Double trouble: how c-MET and HER2 fuel bladder cancer progression

Bladder cancer is still a prevalent, heterogeneous, and challenging disease. Most cases are non-muscle invasive and carry a significant risk of recurrence and progression despite current advances in therapeutic options.

c-MET and HER2 belong to the receptor tyrosine kinase family, which has been intensively studied in cancer. Both receptors are upregulated in bladder cancer and have been connected to tumor development and progression by activating a variety of signaling pathways that control proliferation, migration, and metastasis. C-MET and HER2 are indicators of aggressive bladder cancer and possible therapeutic targets. This review will investigate the contributions of c-MET and HER2 in the genesis and progression of bladder cancer, the implications for therapy and ongoing research in this field.

Targeting c-MET and HER2 together, either as monotherapy or combined therapy, might become promising in managing aggressive bladder cancer.